

## References

- Ben-Shlomo Y, Camfield L, Warner T. What are the determinants of quality of life in people with cervical dystonia? *J Neurol Neurosurg Psychiatry* 2002;**72**:608-614.
- Brashear A, Lew MF, Dykstra DD *et al.* Safety and efficacy of NeuroBloc<sup>®</sup> (botulinum toxin type B) in type A-responsive cervical dystonia. *Neurology* 1999;**53**:1439-1446.
- Brin MF, Lew MF, Adler CH *et al.* Safety and efficacy of NeuroBloc<sup>®</sup> (botulinum toxin type B) in type A resistant cervical dystonia. *Neurology* 1999;**53**:1431-1438.
- Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. *Dis Mon* 2002;**48**:367-383.
- Callaway JE. Botulinum toxin type B (Myobloc<sup>®</sup>): Pharmacology and biochemistry. *Clin Dermatol* 2004;**22**:23-28.
- Claypool D, Duane D, Ilstrup D, Melton III LJ. Epidemiology of outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. *Mov Disord* 1995;**10**(5):608-614.
- Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallet M, editors. *Therapy with Botulinum Toxin*. New York, NY: Marcel Dekker, Inc; 1994:p211-237.
- Comella CL, Jankovic J, Shannon KM *et al.* Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. *Neurology* 2005; **65**:1423-1429.
- Critchfield J, Sanders ME, Setler P. Immunogenicity of botulinum toxin therapy. *CNS Spectrums* 2000;**5**(Suppl 6):S1-8.
- Data on file: Study 351 (Neuro-0001). Eisai Europe Ltd.
- Data on file: Study 352 (Neuro-0003). Eisai Europe Ltd.
- Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. *Brain* 1998;**121**:547-560.
- The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. *J Neurol* 2000;**247**:787-792.
- Factor SA *et al.* Practical considerations for the clinical use of Botulinum toxin Type B. February New York, NY: We Move: 2002.
- Factor SA, Molho ES, Evans S, Feustel PJ. Efficacy and safety of repeated doses of botulinum type B in type A resistant and responsive cervical dystonia. *Mov Disord* 2005;**20**:1152-1160.
- Jahanshahi M, Marsden CD. Depression in torticollis: a controlled study. *Psychol Med* 1988;**18**:925-933.
- Jahanshahi M, Marsden CD. A longitudinal study of depression, disability and body concept in torticollis. *Behav Neurol* 1990;**3**:233-246.
- Jahanshahi M. Psychosocial factors and depression in torticollis. *J Psychosom Res* 1991;**35**:493-507.
- Jankovic J, Fahn S. Dystonic Disorders. In: Jankovic J, Tolosa E, editors. *Parkinson's Disease and Movement Disorders*. Baltimore, MD: Urban & Schwarzenberg: 2002:331-357.
- Jankovic J. In: Goldman L, Ausiello D, editors. *Cecil Textbook of Medicine*. Philadelphia, PA: Sanders: 2004:2312-2314.

Lalli G, Herreros J, Osborne SL *et al.* Functional characterisation of tetanus and botulinum neurotoxins binding domains. *J Cell Sci* 1999;**112**:2715-2724.

Lew MF and Factor SA. A 4 year observational study of repeated dosing with botulinum toxin type B in patients with cervical dystonia [Abstract P05.126]. *Neurology* 2006;**66** (suppl 2):A290-291.

NeuroBloc<sup>®</sup> Summary of Product Characteristics.

Nutt J, Muentner M, Aronson A *et al.* Epidemiology of focal and generalized dystonia in Rochester, Minnesota. *Mov Disord* 1988;**3**(3):188-194.

Pappert EJ. A multi-center, open-label, multiple-dose, dose-escalation, safety and tolerability study of botulinum toxin type B in patients with cervical dystonia. *Mov Disord* 2007;**22**(suppl 16):S123.

Pappert EJ, Germanson T. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, non inferiority trial. *Mov Disord* 2008; **23**(4):510-7.

Pappert EJ *et al.* Botulinum Toxin Type B (NeuroBloc<sup>®</sup>) Dosing: Experience from clinical studies. Poster presented at Toxins, Jun 12-15 2008a, Italy.

Rossetto O, Montecucco C. Chapter 12: How Botulinum Toxin Works in Handbook of Botulinum Toxin Treatment. 2003:9-27.

Setler P. The biochemistry of botulinum toxin type B. *Neurology* 2000;**55**(Suppl 5):S22-S28.

Simpson LL, Maksymowych AB, Park JB, Bora RS. The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. *J Pharmacol Exp Ther* 2004;**308** :857-864.

Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of natural history. *Acta Neurol Belg* 1995;**95**(4):210-215.

Velickovic M, Benabou R, Brin MF. Cervical dystonia pathophysiology and treatment options. *Drugs* 2001;**61**(13):1921-1943.

Yamasaki S, Baumeister A, Binz T *et al.* Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinum neurotoxins and tetanus toxin. *J Biol Chem* 1994;**269**(17):12764-12772.